Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Mecetronium Etilsulfate→

Mecetronium Etilsulfate Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
3006-10-8
Molecular formula
C22H49NO4S
Molecular weight
423.7 g/mol
Drug class
Quaternary ammonium antisepticcationic skin disinfectant
Mechanism of action
A cationic surfactant antiseptic that interacts with microbial cell membranes and disrupts membrane integrity, leading to loss of cellular components and microbial inactivation. Its activity is formulation- and concentration-dependent.
Indications / reported uses
  • Used as a component of topical skin antiseptic and surgical hand-disinfection products, often in combination with other antiseptic agents; the exact product formulation determines the labelled use.

Sources: https://www.ncbi.nlm.nih.gov/mesh/?term=Mecetronium · https://pubchem.ncbi.nlm.nih.gov/#query=mecetronium%20etilsulfate · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Mecetronium Etilsulfate Environmental Risk Assessment (ERA) (the Mecetronium Etilsulfate ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.